Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity (Q40062912)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 August 2008

Language	Label	Description	Also known as
English	Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity	scientific article published on 3 August 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

0 references

toll-like receptor

0 references

author name string

Samar Hamdy

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Ommoleila Molavi

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Zengshuan Ma

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Azita Haddadi

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Aws Alshamsan

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Zahra Gobti

6

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sara Elhasi

7

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

John Samuel

8

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Afsaneh Lavasanifar

9

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

language of work or name

0 references

publication date

3 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

5046-5057

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Immunosuppressive networks in the tumour environment and their therapeutic relevance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Immune system versus tumor: shifting the balance in favor of DCs and effective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Targeting the innate immune response with improved vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Targeting vaccines to dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

New hepatitis B vaccine formulated with an improved adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Taking toll: lipid A mimetics as adjuvants and immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (D,L-lactic-co-glycolic acid) nanoparticle formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

"Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

VEGF as a mediator of tumor-associated immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Melanoma-associated antigens recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Toll-like receptor ligands energize peptide vaccines through multiple paths

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Immunosuppressive strategies that are mediated by tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Immune resistance orchestrated by the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Challenges facing adjuvants for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Natural-killer cells and dendritic cells: "l'union fait la force".

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.035

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.07.035

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40062912&oldid=1883439155"